13D·WATCH Activist + Insider Intelligence Live feed Blog About Pilot
SCHEDULE Filed 2025-07-31 Event 2025-07-23 SEC 0001104659-25-072677 →

Sofinnova Crossover I Abivax S.A. AAVXF

Stake: 11.40% Shares: 9,599,478 CUSIP: 00370M103 Class: Ordinary Shares, par value (euro)0.01 per share

Item 4 — Purpose of Transaction

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: On July 23, 2025, the Issuer announced an underwritten public offering, consisting of 10,156,000 ADSs each representing one ordinary share, EUR0.01 nominal value per share plus an over-allotment option of 1,523,400 ADSs (the "Offering"). The underwriters exercised their over-allotment option in full. At the closing of the Offering on July 28, 2025, the Issuer issued 11,679,400 ADSs. SC purchased 270,000 ADSs pursuant to the Offering. All of the Ordinary Shares that are held of record by the Reporting Persons as reported herein were acquired for investment purposes. The Reporting Persons retain the right to change their investment intent, from time to time to acquire additional Ordinary Shares or other securities of the Issuer, or to sell or otherwise dispose of all or part of the Ordinary Shares or other securities of the Issuer, if any, beneficially owned by them, in any manner permitted by law. The Reporting Persons may engage from time to time in ordinary course transactions with financial institutions with respect to the securities described herein. Except as set forth above, none of the Reporting Persons currently has any plans or proposals which would be related to or would result in any of the matters described in Items 4(a)-(j) of the Instructions to Schedule 13D. However, as part of the ongoing evaluation of investment and investment alternatives, the Reporting Persons may consider such matters and, subject to applicable law, may formulate a plan with respect to such matters, and, from time to time, may hold discussions with or make formal proposals to management or the board of directors of the Issuer or other third parties regarding such matters.

Cross-References

Insider Activity (last 365d)
0 transactions
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
2 13D/G filings on this issuer
1 other filing besides this one
Filer Track Record
2 filings by this filer
1 other filing in the data moat
Short Interest · settle 2026-03-31
DTC 999.99
10,288 shares short · -8.3% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers
1 holder · $392.31M
Point72 Asset Mgmt

Other 13D/G Filings on Abivax S.A.

FiledFormFilerStakeShares
2025-02-14 SCHEDULE Sofinnova Crossover I 11.00% 7,794,478 view →

Other Filings by Sofinnova Crossover I

FiledFormIssuerStakeShares
2025-02-14 SCHEDULE Abivax S.A. AAVXF 11.00% 7,794,478 view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. $1,500/mo. Pilots welcome.

Request a pilot →